FDA Panel Rejects Neuronix’s NeuroAD Device for Treating Alzheimer’s

(Source: BioSpace) The FDA application was based on data from a U.S. trial in 130 Alzheimer’s patients who received six weeks of daily treatment with neuroAD and simultaneous